title: Basic fibroblast growth factor in an animal model of spontaneous mammary             tumor progression.
abstract: Although basic fibroblast growth factor (FGF2) was the first pro-angiogenic molecule discovered, it has numerous activities on the growth and differentiation of non-vascular cell types. FGF2 is both stimulatory and inhibitory, depending on the cell type evaluated, the experimental design used and the context in which it is tested. Here, we investigated the effects of manipulating endogenous FGF2 on the development of mammary cancer to determine whether its endogenous contribution in vivo is pro- or anti-tumorigenic. Specifically, we examined the effects of FGF2 gene dosing in a cross between a spontaneous breast tumor model (PyVT+ mice) and FGF2-/- (FGF KO) mice. Using these mice, the onset and progression of mammary tumors was determined. As predicted, female FGF2 WT mice developed mammary tumors starting around 60 days after birth and by 80 days, 100% of FGF2 WT female mice had mammary tumors. In contrast, 80% of FGF2 KO female mice had no palpable tumors until nearly three weeks later (85 days) at times when 100% of the WT cohort was tumor positive. All FGF KO mice were tumor-bearing by 115 days. When we compared the onset of mammary tumor development and the tumor progression curves between FGF het and FGF KO mice, we observed a difference, which suggested a gene dosing effect. Analysis of the tumors demonstrated that there were significant differences in tumor size depending on FGF2 status. The delay in tumor onset supports a functional role for FGF2 in mammary tumor progression, but argues against an essential role for FGF2 in overall mammary tumor progression.
authors.affiliation: Department of Surgery, School of Medicine, University of California                     San Diego, MC 8236, San Diego, CA 92103, USA.
authors.forename: Steven
authors.initials: S
authors.lastname: Kao
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Mo
authors.forename: Andrew
authors.initials: A
authors.lastname: Baird
authors.forename: Brian P
authors.initials: BP
authors.lastname: Eliceiri
mesh_terms: D000818:Animals; D018450:Disease Progression; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000235:genetics* / Q000502:physiology*; D018628:Gene Dosage; D015674:Mammary Neoplasms, Animal / Q000235:genetics* / Q000473:pathology*; D051379:Mice; D018345:Mice, Knockout; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000096:biosynthesis
chemical_list: D016222:Fibroblast Growth Factor 2; D051496:Receptor, Fibroblast Growth Factor, Type 1